CR20200151A - Compuestos bicíclicos y métodos de utilización de los mismos - Google Patents

Compuestos bicíclicos y métodos de utilización de los mismos

Info

Publication number
CR20200151A
CR20200151A CR20200151A CR20200151A CR20200151A CR 20200151 A CR20200151 A CR 20200151A CR 20200151 A CR20200151 A CR 20200151A CR 20200151 A CR20200151 A CR 20200151A CR 20200151 A CR20200151 A CR 20200151A
Authority
CR
Costa Rica
Prior art keywords
kinase inhibitors
rip1 kinase
bicyclic compounds
compounds
ring
Prior art date
Application number
CR20200151A
Other languages
English (en)
Inventor
Snahel Patel
Craig Stivala
Guiling Zhao
Huifen Chen
Blake Daniels
Gregory Hamilton
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20200151A publication Critical patent/CR20200151A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención proporciona nuevos compuestos que presentan la fórmula general I o sales farmacéuticamente aceptable de los mismos, en los que: RA, RB1, RB2, el anillo A y el anillo B son tal como se indica en la presente memoria, composiciones farmacéuticas que incluyen los compuestos y métodos de utilización de los compuestos.
CR20200151A 2017-10-11 2018-10-10 Compuestos bicíclicos y métodos de utilización de los mismos CR20200151A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762570892P 2017-10-11 2017-10-11
PCT/EP2018/077656 WO2019072942A1 (en) 2017-10-11 2018-10-10 BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1

Publications (1)

Publication Number Publication Date
CR20200151A true CR20200151A (es) 2020-05-23

Family

ID=63840848

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200151A CR20200151A (es) 2017-10-11 2018-10-10 Compuestos bicíclicos y métodos de utilización de los mismos

Country Status (19)

Country Link
US (1) US11673892B2 (es)
EP (1) EP3694858B1 (es)
JP (1) JP7362600B2 (es)
KR (1) KR20200070297A (es)
CN (1) CN111201229B (es)
AU (1) AU2018348930A1 (es)
BR (1) BR112020007067A2 (es)
CA (1) CA3078653A1 (es)
CL (1) CL2020000944A1 (es)
CO (1) CO2020004977A2 (es)
CR (1) CR20200151A (es)
IL (1) IL273443A (es)
MA (1) MA50356A (es)
MX (1) MX2020003439A (es)
PE (1) PE20211246A1 (es)
PH (1) PH12020550253A1 (es)
RU (1) RU2020114670A (es)
SG (1) SG11202003283TA (es)
WO (1) WO2019072942A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
CN119613408A (zh) * 2017-07-14 2025-03-14 豪夫迈·罗氏有限公司 二环酮化合物及其使用方法
MX2020003451A (es) 2017-10-31 2020-08-03 Hoffmann La Roche Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos.
CN113302193B (zh) * 2019-01-11 2026-05-29 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
CN114591333B (zh) * 2020-12-04 2023-08-01 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法
CA3214802A1 (en) * 2021-04-02 2022-10-06 Genentech, Inc. Processes for making bicyclic ketone compounds
WO2023039795A1 (zh) * 2021-09-16 2023-03-23 维泰瑞隆（北京）生物科技有限公司 Rip1激酶抑制剂及其用途
WO2025261418A1 (zh) * 2024-06-19 2025-12-26 成都赜灵生物医药科技有限公司 并芳基类化合物及其用途
WO2026001865A1 (en) * 2024-06-24 2026-01-02 Sironax Ltd. Rip1 modulators, preparations, and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
WO1992004343A1 (fr) * 1990-09-04 1992-03-19 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive de tetrahydrobenzazole
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
EP1007042A4 (en) 1997-06-13 2001-07-04 Sugen Inc NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
CA2416527C (en) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
SI1397364T1 (sl) 2001-05-24 2007-12-31 Lilly Co Eli Novi pirolni derivati kot farmacevtske uäśinkovine
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
EA017937B1 (ru) 2007-02-07 2013-04-30 Пфайзер Инк. ПРОИЗВОДНЫЕ 3-АМИНОПИРРОЛО[3,4-c]ПИРАЗОЛ-5(1H,4H,6H)-КАРБАЛЬДЕГИДА В КАЧЕСТВЕ ИНГИБИТОРОВ РКС
JP2012051806A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
WO2011006903A1 (en) 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
CN103874702B (zh) * 2011-07-15 2015-12-09 杨森制药公司 作为γ分泌酶调节剂的经取代的吲哚衍生物
JP6267193B2 (ja) 2012-05-22 2018-01-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換ジピリジルアミン類及びそれらの使用
MX2015009270A (es) 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
TWI648274B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 （二）
RU2015147601A (ru) 2013-05-01 2017-06-05 Ф. Хоффманн-Ля Рош Аг С-связанные гетероциклоалкилзамещенные пиримидины и их применения
TWI710558B (zh) 2013-05-01 2020-11-21 瑞士商赫孚孟拉羅股份公司 二雜芳基化合物及其用途
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
RU2017109122A (ru) 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
JP6701225B2 (ja) 2015-03-09 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三環式ｄｌｋ阻害剤及びその使用
RU2716136C2 (ru) 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
US9815850B2 (en) * 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
EP3694858B1 (en) 2023-01-11
JP7362600B2 (ja) 2023-10-17
CL2020000944A1 (es) 2020-08-21
CN111201229A (zh) 2020-05-26
CA3078653A1 (en) 2019-04-18
AU2018348930A1 (en) 2020-03-26
SG11202003283TA (en) 2020-05-28
CO2020004977A2 (es) 2020-05-05
WO2019072942A1 (en) 2019-04-18
JP2020536915A (ja) 2020-12-17
US20200283446A1 (en) 2020-09-10
MA50356A (fr) 2021-04-21
PE20211246A1 (es) 2021-07-13
KR20200070297A (ko) 2020-06-17
PH12020550253A1 (en) 2021-02-22
EP3694858A1 (en) 2020-08-19
RU2020114670A (ru) 2021-11-12
US11673892B2 (en) 2023-06-13
CN111201229B (zh) 2024-08-23
BR112020007067A2 (pt) 2020-10-06
IL273443A (en) 2020-05-31
MX2020003439A (es) 2020-07-29

Similar Documents

Publication Publication Date Title
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
PH12020550792A1 (en) Compounds useful for inhibiting cdk7
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MY195977A (en) Heterocyclic Compounds and uses Thereof
MY199735A (en) Jak1 selective inhibitors
PH12016501440A1 (en) Novel heterocyclic compounds
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
TW201613864A (en) Novel compounds
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MY194873A (en) Fused Bicyclic Heteroaryl Derivatives Having Activity as Phd Inhibitors
MY194116A (en) Pharmaceutical compounds
MX2018014813A (es) Composiciones antibacterianas.
PH12020550537A1 (en) Bicyclic sulfones and sulfoxides and methods of use thereof
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
JOP20190163B1 (ar) منشط nrf2
MX2017013885A (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
IN2014MU00859A (es)
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2018010652A (es) Composiciones farmaceuticas.
MX2016012646A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
EA202090930A1 (ru) Соединения, пригодные для ингибирования cdk7
MY182697A (en) Bicyclic lactams and methods of use thereof